Pediatrix Medical (MD) EBITDA (2009 - 2026)

Pediatrix Medical (MD) has 18 years of EBITDA data on file, last reported at $29.0 million in Q1 2026.

• EBITDA for Q1 2026 came in at $29.0 million, up 34.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $174.6 million (up 316.87% YoY), and the FY2025 annual result was $167.1 million, up 270.61% from the prior year.
• EBITDA retreated to $29.0 million in Q1 2026 per MD's latest filing, from $33.8 million in the prior quarter.
• Over five years, EBITDA peaked at $72.0 million in Q3 2025 and troughed at -$152.8 million in Q2 2024.
• A 5-year average of $5.9 million and a median of $25.9 million in 2022 frame the typical range for EBITDA.
• The sharpest annual moves came in 2024 and 2025: EBITDA sank 647.86% in 2024, then soared 425.42% in 2025.
• A 5-year view of EBITDA shows it stood at $30.0 million in 2022, then tumbled by 509.61% to -$123.0 million in 2023, then jumped by 124.08% to $29.6 million in 2024, then gained by 14.28% to $33.8 million in 2025, then fell by 14.21% to $29.0 million in 2026.
• Business Quant data shows MD's EBITDA at $29.0 million in Q1 2026, $33.8 million in Q4 2025, and $72.0 million in Q3 2025.